Scarica l'app Stockscreener
19.95
1.68%
-0.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$20.29
Aprire:
$20.51
Volume 24 ore:
1.98M
Relative Volume:
0.87
Capitalizzazione di mercato:
$3.32B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
110.83
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-0.45%
1M Prestazione:
+11.51%
6M Prestazione:
+25.24%
1 anno Prestazione:
-19.78%
Intervallo 1D:
$19.92
$20.68
Intervallo di 1 settimana:
$19.52
$20.68
Portata 52W:
$14.15
$26.56
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
19.95 | 3.32B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Director Commercial Launch Excellence and PlanningAcadia Pharmaceuticals Inc. - Built In
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
ACADIA Pharmaceuticals (ACAD) to Release Quarterly Earnings on Tuesday - MarketBeat
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
JP Morgan Week 2025 – Catherine Owen Adams - pharmaphorum
ACADIA Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating - Investor's Business Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Down 5.2% in January - MarketBeat
Acadia Pharmaceuticals Turns Heads with Ambitious Stock Awards - mivalle.net.ar
Biotech Giant Acadia Pharmaceuticals Lures Talent with Slick New Stock Incentives - Jomfruland.net
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 14, 2025 - BioSpace
ACADIA Pharmaceuticals (NASDAQ:ACAD) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock? - MSN
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy' - Seeking Alpha
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Deutsche Bank Initiates Coverage of ACADIA Pharmaceuticals (ACAD) with Hold Recommendation - MSN
Acadia's Q4 Results Coming: Major Updates on Breakthrough Parkinson's and Rett Syndrome Treatments - StockTitan
Deutsche Bank sets Acadia Pharmaceuticals stock target at $22 By Investing.com - Investing.com Nigeria
Deutsche Bank sets Acadia Pharmaceuticals stock target at $22 - MSN
Deutsche Bank Initiates Coverage on ACADIA Pharmaceuticals With Hold Rating, $22 Price Target - Marketscreener.com
Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market Research - GlobeNewswire Inc.
BlackRock, Inc. Increases Stake in ACADIA Pharmaceuticals Inc. - GuruFocus.com
High Growth Tech Stocks To Watch In February 2025 - Simply Wall St
Schizophrenia Market Expected to rise, 2034 | Boehringer - openPR
Leerink Partnrs Brokers Increase Earnings Estimates for ACAD - MarketBeat
Leerink Partnrs Has Optimistic Outlook of ACAD Q4 Earnings - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - Defense World
Q4 EPS Estimate for ACADIA Pharmaceuticals Raised by Analyst - Defense World
DCGI nod to Bajaj Healthcare for manufacturing Parkinson's disease psychosis drug Pimavanserin in India - Medical Dialogues
ACADIA Pharmaceuticals' SWOT analysis: stock outlook amid mixed product performance - MSN
3 Hidden Bargains in the Healthcare Sector - Inkl
VTRS: 3 Hidden Bargains in the Healthcare Sector - StockNews.com
How Biopharma Leaders Are Leveling Up Sales Strategies For 2025 - FiercePharma
Acadia’s New CEO Outlines Growth Strategy - News & Insights
Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.25 - MarketBeat
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Up 6.4%Still a Buy? - MarketBeat
Research Analysts Offer Predictions for ACAD FY2025 Earnings - Defense World
Brokers Issue Forecasts for ACAD FY2025 Earnings - MarketBeat
SG Americas Securities LLC Increases Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis - MarketBeat
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 6.9%Time to Sell? - MarketBeat
JPM25: After taking the wheel at Acadia, CEO Catherine Owen Adams looks to steer firm toward $1B in sales - FiercePharma
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):